Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 3,663 shares, a growth of 142.1% from the June 30th total of 1,513 shares. Based on an average daily volume of 9,213 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

Elekta Stock Performance

Shares of Elekta stock opened at $4.93 on Tuesday. Elekta has a one year low of $4.35 and a one year high of $6.93. The company has a market cap of $1.82 billion, a PE ratio of -30.83 and a beta of 1.01. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87. The business has a 50-day simple moving average of $5.37 and a 200-day simple moving average of $5.88.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. The business had revenue of $521.00 million for the quarter. On average, equities research analysts forecast that Elekta will post 0.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Elekta from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.